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ABSTRACT
Mathematical models are often used in describing immune response to HIV
infection, and treatment against HIV infection can be improved through the study of
these descriptions. One such model from Kirschner and Webb's paper, "Immunotherapy
ofHIV-1 Infection," uses a system of two differential equations to model the interaction
of the AIDS virus and CD4+ T -cells. Beginning with this existing model, we modify the
equations to include the mathematical representation of a theoretical antiviral treatment
based on maximizing the benefit to the patient. Solving this problem requires both
analytic and numerical evaluations, and a numerical example is provided to illustrate the
form of a treatment schedule. In solving the optimal control problem we learn how to
best administer such a treatment to extend the life of the patient.

I. Introduction:
Mathematical models provide great insight into the workings of many biological
environments. Quantifying the living world helps in the understanding of the dynamics within
organisms and assists in medical studies, environmental studies, and other areas of biological
benefit In medicine specifically, mathematical models can represent the actions of disease, and
medical researchers can find optimal ways of treating infection through the use of such models.
By the understanding of the dynamics of the immune system and its responses, the study of
medicine can advance in efficiency of treatments.
Many different researchers have considered the immune system's mathematical basis,
recognizing the potential for describing immune cell numbers in terms of simple population
models. When infectious cells, viruses, bacteria, etc., enter the body, the relationship between
immune cells and invading cells becomes much like a predator-prey relationship. When the body
becomes infected with the Human Immunodeficiency Virus, however, the system immediately
becomes more complicated. Many researchers and mathematicians have dealt with the topic of

mv infection described through mathematical modeling, and hopefully their work will help in the
treatment of the terminal disease. The different models have their own advantages and
disadvantages so one model will not necessarily lead to the "cure" for mv infection. Through
the study of these models, researchers can continually make improvements to the existing systems
and hopefully achieve the best treatment possible.
Control theory is the mathematical study of adjusting features of systems to achieve
desired goals. When relating control theory to medical models such as those involving HIV
infection, we must consider the patient's threshold for treatment while we strive for the highest
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achievable results of patient benefit (Fleming 2). Using an existing model from "Immunotherapy
ofHIV-Infection" (Kirschner 73-74), we mathematically controlled the system in order to find the
best way to administer a certain type of treatment for the infection. The theoretical treatnlent
used in this evaluation fights HIV by inhibiting the proliferation of virus particles by infected Tcells. By using control theory, we hoped to find an analytica1lnumerical representation of
treatment that maximizes benefit to the patient.

II. Existing HIV Modeling
Mathematical models of HIV infection vary in many respects, but all basically begin with
the underlying idea somewhat similar to a predator-prey or competition relationship. Because
HIV infects immune cells themselves, the relationship between T -cells and HIV becomes very
complicated. HIV models have many factors to consider, and some models involve several
equations. One system from "Mathematical Analysis of Antiretroviral Therapy Aimed at HIV-1
Eradication or Maintenance of Low Viral Loads" models HIV infection with a ten differential
equation model (Wein 83). Models ofHIV infection range from highly complex to fairly simple,
varying in assumptions and in the populations considered.
The majority of mathematical models of viruses concern HIV-1, for HIV-1 is the most
studied human virus (Regoes 451). As stated in "Virus Dynamics: the Effect of Target Cell
Limitation and Immune Responses on Virus Evolution," seven assumptions underlie the theory of
HIV-1 progression. These assumptions are
(I) virus load causes disease; (ii) immune responses reduce virus load; (iii) HIV-1
can impair immune responses by killing CD4 cells; (iv) there is continuous and
rapid virus replication throughout the course of infection; (v) the rapid turnover
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leads to a large number of virus mutants; (vi) some of these mutants can escape
from immune responses; (vii) the virus may evolve towards faster replication rates
during infection (451-452).
Although not all models incorporate mutations, these assumptions relate the basic idea of the
situation being modeled.
One specific model of the dynamics of mv infection is "Immunotherapy of mV-1
Infection" by D.E. Kirschner and G.F. Webb. This paper assesses the benefit of using
interleukins, a specific type of cytokine, to boost the immune response to the infection (Kirschner
71). Kirschner and Webb model the immune response to mv-1 infection using only the
populations of virus particles and of T -cells. They do not use different states of the T -cells (e. g.,
infected and latent, infected and actively producing virus), and hence their model is relatively
simple in comparison to many other existing models. Kirschner and Webb's work resulted in the
two equation system of ordinary differential equations,
dT
dt
dV
dt

= sl - (s2)V - JlT - kVT
(b1 + V)
- cVT
(b2 + V)

in which T represents the concentration of CD4+ T -cells as a function of time and V represents
the concentration of free virus particles as a function of time. The first two terms of dT/dt
represent the source and proliferation of healthy CD4+ T -cells and s 1=20 and s2= 1. 5. The values
b1 and b2 are half saturation constants and they equal 14.0 and 1.0, respectively. The value -JlT
is a natural death term and -kVT involves the loss of T -cells to viral infection. The value Jl, death
rate ofuninfected T-cells, is 0.002; and k, the rate of infection by free virus, is 2.5*10A-4. The
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term gV/(b2 + V) involves virus proliferation from several areas other than plasma such as the
lymph system. The value g, input rate of external viral source, is 30. The initial value for T for
the model is 1000.0, but three different values in different versions of the paper are listed for
initial V: 1.0, 1000, 3000. The model is fundamentally a modified predator-prey or (more
accurately) competition relationship with interaction terms of -kVT and -cVT. (In their paper,
Kirschner and Webb further modified the system with a drug input function r(t) representing the
interleukin treatment by adding the term r(t)T to the dT/dt equation.)

III. Implementation of the Antiviral Function
The original system devised by Kirschner and Webb was re-evaluated in its original form
and modified to include an antiviral treatment inhibiting the production of virus particles. Using
control theory, the optimal treatment schedule can be calculated for this treatment. Because the
treatment affects virus proliferation, the effect of the control function u(t) is the coefficient of the
proliferation term for the virus population. For controls u(t) such that .1 < u(t) < .9, our state
system is
dT
dt

dV =
dt

2.0 -

- .002T - (2.5*101\(-4))VT
(14.0 + V)

30V( .9-u(t) )
(1.0 + V)

- .007VT .

IV. Evaluation of the System
When creating the best situation for the patient, we must consider both the positive and
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negative results of the treatment. In order to maximize the benefit to the patient, we must
maximize the objective functional,

t1

J( T(t) - (l;2)PU2(t) ) dt

o

which represents the benefit to the immune system through increased concentration of T -cells
minus the systemic cost of the treatment. By finding u*(t), the optimal treatment which
maximizes this integral, we find the treatment schedule which provides the greatest overall benefit
to the patient. When maximizing this integral, we must first find and utilize the Hamiltonian of the
system,
H

( T -(l;2)pu2(t) ) + AI(dT/dt) + A2(dV/dt),

where Al and A2 are functions dependent on values ofT, V, and time (Kamien 124-128). Solving
the optimality equation,

aH/au

= 0, gives the optimal equation for the treatment,

{ 0.1
-A2*30V
u*(t) = { -------------P*(1.0+V)

{ 0.9

u < 0.1

0.1 <u<0.9

u>0.9

The adjoint equations, A1'=(-BHlBT) and A2'=(-BHlBV), evaluated from the Hamiltonian are
Al '=AI *(.002+.007V) + A2*(2.5*10A(-4)V - 1.0
A2'=A1 *(

21.0 + (2.5*10A(-4»T ) - A2*( 27.0-30u -.007T)
(14.0+v)2
(1.0+V)2
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which are necessary in finding the numerical solution of the modified system. To determine if
these equations do in fact produce a maximum value for the functional, we must verify that the
second partial derivative of the Hamiltonian with respect to u*(t) is negative. We find that

8ZHlau z

-~;

therefore, choosing

~>O

will make u*(t) the optimal treatment function.

Solving the model itself must be done numerically. The original model was re-solved
using the classic Fourth Order Runge-Kutta method written in a Fortran code (Appendix A). The
values of the T -cells decrease and the values of the virus increase so quickly initially that an
extremely small step-size must be used or the values will become negative.

The initial

concentration ofT-cells, TO, was set at 500.0 in the newly modified system rather than
TO=1000.0 as in the original paper. The initial value was lowered in order to simulate a later
stage of infection. The original model lists three initial values for the virus population in two
different copies of the paper (one copy prior to publication), but the value 1000.0 was used in this
evaluation because this value was included in the actual published result and the re-evaluation
results seemed logical. The value

~= 124.0

was chosen because it provided the best results and

did not violate the condition 13>0. The optimality system, which is the original T(t) and V(t)
ODEs coupled with adjoint ODEs including the control u*(t), was evaluated using an iterative
method with the Classic Fourth Order Runge-Kutta Method in a FORTRAN code (Appendix B).
Numerical solutions were found for the resulting functions of the T-cell population with respect to
time, the virus population with respect to time, as well as the treatment schedule over time. The
nunlerical results for the original system and the optimized system were computed in the
respective FORTRAN codes then graphed using MATLAB.
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V. Results and Discussion
The virus population values decrease in the presence of treatment (Figure 1 and Figure 2)
although the results do not appear to be drastic. The numerical results to the original system
show a steady decline in the T-cell population (Figure 3), but the population of the T -cells
behaves quite differently in the presence of treatment. The positive change in T-cell numbers in
the presence of treatment is quite obvious (Figure 4), with T-cell numbers increasing over the
majority of the treatment period and gradually declining near the end of the treatment period.
Hence, the treatment schedule does appear to increase the T-cell population over the course of
treatment and therefore seems to benefit the patient. The numerical results for u*(t), the
treatment schedule (Figure 5). includes high levels of treatment at the beginning of the treatment
period with the dosage decreasing over the course of treatment. This result suggests that an
intense treatment is very beneficial initially in the treatment schedule, but maintaining that strength
of treatment would not result in the overall best situation for the patient. Most likely the negative
effects of the drug outweigh the benefits of high treatment levels as time progresses.
Although the treatment discussed here is theoretical, current treatments exist inhibiting
different stages ofillV infection which affect the progression of the disease in various major
ways, including the prevention of binding ofHIV to the surface of the host cell and the inhibition
of reverse transcription of RNA from the HIV particle into T-cell DNA. The treatment evaluated
in this paper is assumed to treat through inhibition of one or more stages of viral production. The
combined use of different treatments, i.e., a "drug cocktail," has the potential for highly favorable
results. By using optimal treatment schedules, we can best combine these various treatments to
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benefit patients.
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Appendix A

c
.c
c
c

This program solves a
of differential equations modeling
the action of the immune system in response to HIV infection.
The
model comes from "Immunotherapy of HIV-l Infection," D.E. Kirschner
and G.F. Webb, Journal of Biological Systems.
implicit none
real ti, tf, h, t, v
integer n, i
real xn(2,1001), xl, x2, kx(2,4)

c The original differential equations are entered:
xl (t,v)
x2(t,v)

2.0 - (1.5*v)/(14.0+v) - .002*t 30.0*v/{1.0+v)
.007*v*t

(2.5e-4)*v*t

c Initialize values:
n = 1000
ti = 0.0
tf = 100.0
h = (tf-ti)/n
c Initial values are set for the loop:
xn(l,l)
xn{2,l)

= 500.0
1000.0

c Begin the loop using R-K:
DO i=l,n+l
kx(l,l)=h*xl(xn{l,i),xn(2,i»
kx(2,l)=h*x2(xn(l,i),xn(2,i»
kx(l,2)=h*xl(xn(l,i)+kx(l,l)/2,xn(2,i)+kx(2,l)/2)
kx(2,2)=h*x2(xn(l,i)+kx(l,l)/2,xn(2,i)+kx(2,l)/2)
kx(l,2)=h*xl(xn(l,i)+kx(1,1)/2,xn(2,i)+kx(2,l)/2)
kx(2,2)=h*x2(xn(l,i)+kx(1,1)/2,xn(2,i)+kx(2,l)/2)
kx(l,3)=h*xl(xn(l,i)+kx(l,2)/2,xn(2,i)+kx(2,2)/2)
kx(2,3)=h*x2(xn(1,i)+kx(1,2)/2,xn(2,i)+kx(2,2)/2)
kx(l,4)=h*xl(xn(l,i)+kx(l,3),xn(2,i)+kx(2,3»
kx(2,4)=h*x2(xn(l,i)+kx(1,3),xn(2,i)+kx(2,3»
c Move t

and v values forward in time:
xn(l,i+l)=xn(1,i)+(kx(1,1)+2*kx(1,2)+2*kx(l,3)+kx(l,4) )/6
xn(2,i+l)=xn(2,i)+(kx(2,l)+2*kx(2,2)+2*kx(2,3)+kx(2,4»16
print*,i,xn(1,i+l),xn(2,i+l)

c

ENDDO
print*,xn(1,n+l),xn(2,n+l)
stop
end

AppendixB

c
c
c
c
c
c

This program solves a system of differential equations modeling
the action of the immune system in response to HIV infection.
The
model comes from "Immunotherapy of HIV-1 Infection," D.E. Kirschner
and G.F. Webb, Journal of Biological Systems.
The original system
is modified to include a theoretical antiviral chemotherapy
treatment.
implicit none
real ti,tf,h,t,v,adj1,adj2,uavg,xntavg,xnvavg,c
real beta,eps,tol,epsx1,epsx2,epsy1,epsy2
integer n,i,counter,L,k,m,j,ii,p,q,s
real xn{2,1001),yn{2,1001),x1,x2,y1,y2,kx{2,4),ky{2,4)
real u(1001),xold{2,1001),yold{2,1001)

c The original differential equations are entered:
x1{t,v) = 2.0 - (1.5*v)/{14.0+v) - .002*t
(2.5e-4)*v*t
x2{t,v,c)
30.0*v*{.9-c)/{1.0+v)
.007*v*t
y1{adj1,adj2,v) = adj1*{.002+.007*v)+adj2*{2.5e-4)*v-1.0
y2{adj1,adj2,t,v,c) = adj1*({21.0/«14.0+v)*{14.0+v»)+
! (2.5e-4)*t)-adj2*«27.0-30.0*c)/«1.0+v)*(1.0+v»-.007*t)
c Initialize values:
n = 1000
ti
0.0
tf = 100.0
h = (tf-ti)/n
beta
124.0
tol
10.0
c Initial values are set for the loops:
xn(l,l) = 500.0
xn(2,l} = 1000.0
DO j=l,n
yn(l,j)=1.0
yn(2,j)=-1.0
ENDDO
yn{l,n+1}=0.0
yn(2,n+1)=0.0
c Initialize "old" values to be compared to xn,yn:
DO m=l,n+1
xold(l,m)=500.0
xold{2,m) 1000.0
yold (1, m) 1. 0
yold(2,m) 1.0
ENDDO
c Begin the loop using R-K:
25

counter=O
counter=counter+1
DO i=l,n

c Here, need to add small loop for u bdd by M:
u(i)=«-1.0)*yn(2,i)*30.0*xn(2,i»/(beta*{1.0+xn(2,i»)
if (u (i) . It. .1) then
u(i} .1
elseif(u(i) .gt . . 9) then
u(i)=.9

endif
uavg=(u(i)

+ u(i+1»/2.0

kx(l,l)=h*x1(xn(l,i),xn{2,i»
kx{2,l)=h*x2(xn(l,i),xn(2,i),u(i»
kx{l,2)=h*x1(xn(l,i)+kx(l,l)/2,xn{2,i)+kx(2,l)/2)
kx(2,2)=h*x2(xn(l,i)+kx(l,l)/2,xn(2,i)+kx(2,l)/2,uavg)
kx(l,3)=h*x1(xn(l,i)+kx(l,2)/2,xn(2,i)+kx(2,2)/2)
kx(2,3)=h*x2(xn(l,i)+kx{l,2)/2,xn(2,i)+kx(2,2)/2,uavg)
kx(l,4)=h*x1(xn(l,i)+kx(l,3),xn(2,i)+kx(2,3»
kx(2,4)=h*x2(xn(l,i)+kx(l,3),xn(2,i)+kx(2,3),u(i+1»
c Move t

and v values forward in time:
xn(1,i+1)=xn(1,i)+(kx(l,l)+2*kx(1,2)+2*kx(l,3)+kx(l,4»/6.0
xn(2,i+1)=xn(2,i)+(kx(2,l)+2*kx(2,2)+2*kx(2,3)+kx(2,4»/6.0

c

c

print*,xn(1,i+1),xn(2,i+1)
ENDDO
print*,xn(l,n+1),xn(2,n+1)

c Begin loop for R-K for adjoints:
DO ii=l,n
c Here, need to add small loop for u bdd by M:
u(ii)=«-1.0)*yn(2,ii)*30.0*xn(2,ii»/(beta*(1.0+xn(2, i i » )
if (u (ii) .It. .1) then
u(ii)=.l
elseif (u(ii) .gt . . 9) then
u(ii)=.9
endif
L=2+n-ii
xntavg=(xn{1,L)+xn(l,L-1»/2.0
xnvavg=(xn(2,L)+xn(2,L-1»/2.0
uavg=(u(L)+u(L-1»/2.0
ky(l,l)=-h*y1(yn(l,L),yn(2,L),xn(2,L»
ky(2,1)=-h*y2(yn(l,L),yn(2,L),xn{l,L),xn(2,L),u(L»
ky(l,2)=-h*y1(yn(l,L)+ky(l,l)/2,yn(2,L)+ky(2,l)/2,xnvavg)
ky(2,2)=-h*y2(yn(l,L)+ky(l,l)/2,yn(2,L)+ky(2,l)/2,xntavg,
!xnvavg,uavg)
ky(l,3)=-h*y1(yn(l,L)+ky(l,2)/2,yn(2,L)+ky(2,2)/2,xnvavg)
ky(2,3)=-h*y2(yn(l,L)+ky(l,2)/2,yn(2,L)+ky(2,2)/2,xntavg,
!xnvavg,uavg)
ky(l,4)=-h*y1(yn(l,L)+ky(l,3),yn(2,L)+ky(2,3),xn(2,L-1»
ky(2,4)=-h*y2(yn(l,L)+ky(l,3),yn(2,L)+ky(2,3),xn(l,L-1),
!xn(2,L-1),u(L-1»
c Move adjoint values in time:
yn(l,L-1)=yn(l,L)+(ky(l,l)+2*ky(l,2)+2*ky(l,3)+ky(l,4))/6.0
yn(2,L-1)=yn(2,L)+(ky(2,1)+2*ky(2,2)+2*ky(2,3)+ky(2,4»/6.0
c

print*,yn(l,L+1) ,yn(2,L+1)

ENDDO
print*,yn(l,L+l),yn(2,L+l)
Need to check if control is working as an antiviral:
epsxl=O.O
epsx2=0.0
epsyl=O.O
epsy2=0.0
DO p=l,n+l
epsxl
epsx2
epsyl
epsy2
ENDDO

epsxl
epsx2
epsyl
epsy2

+
+
+
+

abs(xn(l,p)-xold(l,p»
abs(xn(2,p)-xold(2,p»
abs(yn(l,p)-yold(l,p»
abs(yn(2,p)-yold(2,p»

eps = epsxl + epsx2 + epsyl + epsy2
if

!'

(eps .It. toll then
print*, 'convergence after',counter, 'iterations'
print*
print*, 'T-cell:
Adjl:
Virus:
Adj2:
u: '
DO k=l,n+l,20
print*,k,' ',xn{l,k),' , ,xn(2,k),' , ,yn(l,k),' , ,yn(2,k),
',u(k)
ENDDO
print*
print*, 'final values:'
print*, 'T-cell:' ,xn(l,n+l) ,'Virus:',xn(2,n+l)
print*, 'Adjl:',yn(l,n+l), 'Adj2:',yn(2,n+l)
goto 45

elseif (counter .gt. 20) then
print*, 'convergence not reached'
print*, 'last values are:'
DO s=l,n+l,50
print*,xn(l,k),' , ,xn(2,k),' , ,yn(l,k),'
ENDDO
print*, 'exiting .... '
goto 45
else
DO q=l,n+l
xold(l,q)=xn{l,q)
xold(2,q)=xn(2,q)
yold(l,q)=yn(l,q)
yold{2,q)=yn{2,q)
ENDDO
goto 25
endif
stop
end

',yn{2,k),'

, ,u{k)

